# Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Source: https://onco.cc/trials/nct07278479/  
OnCo record `nct07278479` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of [212Pb]Pb-MP0712 in neuroendocrine tumours, small-cell lung cancer, pancreatic ductal adenocarcinoma and bladder & urothelial cancer, run by Molecular Partners AG, now recruiting.

## Summary

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT07278479 by Molecular Partners AG, with 138 participants planned, started 2026-05-18 and due to reach its primary completion in 2028-09. Interventions recorded: [212Pb]Pb-MP0712.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07278479
- Phase: 1/2
- Setting: A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- Sponsor: Molecular Partners AG
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07278479: https://clinicaltrials.gov/study/NCT07278479

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Molecular Partners](https://onco.cc/companies/molecular-partners/), [Orano Med](https://onco.cc/companies/orano-med/)

---
JSON: https://onco.cc/api/v1/entities/nct07278479.json